BioSpace News Archive

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 12:25 PM ET. LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and imp

- National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and debilitating neurodegenerative diseases - Biohaven Pharmaceuticals, the first industry sponsor of the Collaborative, is currently conducting a Phase 3 clinical trial of troriluzole for Spinocerebellar Ataxia (SCA)

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference. Presentation details: Date: Tuesday, Nov. 17, 2020 Time: 5:35 p.m. GMT ( 12:35 p.m. EST

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of Mark Graf and Eric Motley to the Com

Medicure Inc.cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30 , 2020. Quarter Ended September 30, 2020 Highlights:

Combination with MorphoSys’ antibody know-how enables discovery and development of next-generation T-cell engager molecules

“A person’s HLA type is a piece of critical information needed for biologic drug safety research. We are now seeing a surge in demand for HLA-typed primary cells as researchers look to build ever-more predictive preclinical models for their personalized therapies.

Submitted a premarket approval (PMA)to the FDA for LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN)

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Wolfe Research’s 2nd Annual Virtual Healthcare Conference, which will be webcast on Wednesday, November 18, 2020

QIAreach™ SARS-CoV-2 Antigen Test, developed in partnership with Ellume, is an important step towards decentralized mass screening by processing samples in 2–15 minutes Digital results for dozens of samples per hour and the ability to process antibody tests in parallel, setting new standards in scalability and flexibility Test submitted to FDA for Emergency Use Authorization for US, CE-IVD marking for European Union and other m